ID

19606

Description

Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00398437

Lien

https://clinicaltrials.gov/show/NCT00398437

Mots-clés

  1. 14/01/2017 14/01/2017 -
  2. 15/01/2017 15/01/2017 -
  3. 20/09/2021 20/09/2021 -
Téléchargé le

15 janvier 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00398437

Eligibility Breast Cancer NCT00398437

Criteria
Description

Criteria

histologically confirmed breast cancer
Description

Breast Carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C0678222
stage iv disease
Description

Disease TNM clinical staging

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3258246
her2/neu-overexpression (3+ by immunohistochemistry and/or gene amplification by fluorescence in situ hybridization)
Description

ERBB2 Protein Overexpression Immunohistochemistry | HER2 gene amplification Fluorescent in Situ Hybridization

Type de données

boolean

Alias
UMLS CUI [1,1]
C1515560
UMLS CUI [1,2]
C0021044
UMLS CUI [2,1]
C1512127
UMLS CUI [2,2]
C0162789
undergoing treatment with trastuzumab (herceptin®) (alone or together with chemotherapy) once weekly or 3 times weekly and has achieved responding or stable disease for ≥ 12 weeks
Description

trastuzumab frequency | Herceptin Frequency | Chemotherapy Frequency | Disease Response | Stable Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C0376249
UMLS CUI [2,1]
C0338204
UMLS CUI [2,2]
C0376249
UMLS CUI [3,1]
C0392920
UMLS CUI [3,2]
C0376249
UMLS CUI [4]
C1704632
UMLS CUI [5]
C0677946
no cns metastases (i.e., brain parenchymal lesions and/or leptomeningeal carcinomatosis)
Description

CNS metastases | Lesion of brain Parenchymal | Meningeal Carcinomatosis

Type de données

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C0221505
UMLS CUI [2,2]
C0682552
UMLS CUI [3]
C0220654
no uncontrolled metastatic disease at study entry
Description

Neoplasm Metastasis Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0205318
hormone receptor status
Description

Hormone Receptor Status

Type de données

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0449438
not specified
Description

Unspecified

Type de données

boolean

Alias
UMLS CUI [1]
C0205370
patient characteristics:
Description

Client Characteristics

Type de données

boolean

Alias
UMLS CUI [1]
C0815172
female
Description

Gender

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
menopausal status not specified
Description

Menopausal Status Unspecified

Type de données

boolean

Alias
UMLS CUI [1,1]
C1513126
UMLS CUI [1,2]
C0205370
karnofsky performance status 70-100%
Description

Karnofsky Performance Status

Type de données

boolean

Alias
UMLS CUI [1]
C0206065
no contraindication to mri scan
Description

Medical contraindication MRI Scan

Type de données

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0917711
prior concurrent therapy:
Description

Therapeutic procedure

Type de données

boolean

Alias
UMLS CUI [1]
C0087111
see disease characteristics
Description

disease characteristic

Type de données

boolean

Alias
UMLS CUI [1]
C0599878

Similar models

Eligibility Breast Cancer NCT00398437

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Breast Carcinoma
Item
histologically confirmed breast cancer
boolean
C0678222 (UMLS CUI [1])
Disease TNM clinical staging
Item
stage iv disease
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
ERBB2 Protein Overexpression Immunohistochemistry | HER2 gene amplification Fluorescent in Situ Hybridization
Item
her2/neu-overexpression (3+ by immunohistochemistry and/or gene amplification by fluorescence in situ hybridization)
boolean
C1515560 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C1512127 (UMLS CUI [2,1])
C0162789 (UMLS CUI [2,2])
trastuzumab frequency | Herceptin Frequency | Chemotherapy Frequency | Disease Response | Stable Disease
Item
undergoing treatment with trastuzumab (herceptin®) (alone or together with chemotherapy) once weekly or 3 times weekly and has achieved responding or stable disease for ≥ 12 weeks
boolean
C0728747 (UMLS CUI [1,1])
C0376249 (UMLS CUI [1,2])
C0338204 (UMLS CUI [2,1])
C0376249 (UMLS CUI [2,2])
C0392920 (UMLS CUI [3,1])
C0376249 (UMLS CUI [3,2])
C1704632 (UMLS CUI [4])
C0677946 (UMLS CUI [5])
CNS metastases | Lesion of brain Parenchymal | Meningeal Carcinomatosis
Item
no cns metastases (i.e., brain parenchymal lesions and/or leptomeningeal carcinomatosis)
boolean
C0686377 (UMLS CUI [1])
C0221505 (UMLS CUI [2,1])
C0682552 (UMLS CUI [2,2])
C0220654 (UMLS CUI [3])
Neoplasm Metastasis Uncontrolled
Item
no uncontrolled metastatic disease at study entry
boolean
C0027627 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Hormone Receptor Status
Item
hormone receptor status
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Unspecified
Item
not specified
boolean
C0205370 (UMLS CUI [1])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Menopausal Status Unspecified
Item
menopausal status not specified
boolean
C1513126 (UMLS CUI [1,1])
C0205370 (UMLS CUI [1,2])
Karnofsky Performance Status
Item
karnofsky performance status 70-100%
boolean
C0206065 (UMLS CUI [1])
Medical contraindication MRI Scan
Item
no contraindication to mri scan
boolean
C1301624 (UMLS CUI [1,1])
C0917711 (UMLS CUI [1,2])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
disease characteristic
Item
see disease characteristics
boolean
C0599878 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial